Shenzhen Wankesen Biotechnology Co., Ltd. (hereinafter referred to as "Wankesen") has made significant progress in the construction of its Yangling R&D Center, with the modernized laboratory soon to be put into use. This important strategic layout of Wankesen in the Northwest region is undertaken by the Yangling subsidiary company, bearing the crucial mission of industrializing the company's immersion nanovaccine technology for aquatic animal vaccines. This technological achievement will strongly promote breakthrough progress in China's aquatic animal disease prevention and control technology, filling technical gaps in key areas such as fish disease prevention and control, disease research, and process development for the industry.

  Chairman Wang Wenbo of Wankesen stated that the company's investment and construction in Yangling is not only the establishment of infrastructure but also the industrialization realization of a complete solution for aquatic animal disease prevention and control. The company's core product, the immersion nanovaccine for aquatic animals, represents the advanced technological level in the field of aquatic animal disease prevention and control today and is a revolutionary new veterinary drug product. Wang Wenbo further elaborated on the product's market value, emphasizing that the disease risks faced by the aquaculture industry have always been the core pain point restricting industrial development. Vaccines, as a fundamental means of prevention, are self-evident in their importance. Wankesen's immersion nanovaccine for aquatic animals can establish an effective disease prevention system for major farmed species such as tilapia and carp, addressing disease threats at the source, providing key technical support for the healthy development of the smart aquaculture industry, and achieving the goal of reducing costs and increasing efficiency.

Wankesen is an innovative enterprise focused on aquatic animal disease protection, currently managing over 10 Class I new veterinary drug product pipelines for aquatic animals, possessing strong R&D capabilities and industrialization capacity.

    The company's core technology, the immersion nanovaccine for aquatic animals technology, was transformed from the in-depth research of the aquatic research team led by Professor Wang Gaoxue from the College of Animal Science and Technology at Northwest A&F University. This technology is the result of more than 20 years of dedicated research and development. So far, it has obtained 15 invention patents, with high technological maturity and a solid industrial foundation.    

    The Wankesen project is a typical representative of the deep integration of industry, academia, and research, reflecting the successful practice of transforming university scientific research achievements into industrial applications. Wankesen has established a close cooperative relationship with Northwest A&F University, fully utilizing the university's scientific research advantages and talent resources to promote the transformation of laboratory technologies into commercial products.